Global Parkinson's Disease Treatment Market

1 INTRODUCTION OF GLOBAL PARKINSON'S DISEASE TREATMENTMARKET
1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET INTELLIGENCE
3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL PARKINSON'S DISEASE TREATMENTMARKETOUTLOOK
4.1 Overview
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis
4.5 Regulatory Framework

5 GLOBAL PARKINSON'S DISEASE TREATMENT MARKET, BY PATIENT CARE SETTING:
5.1 Clinics
5.2 Hospitals

6 GLOBAL PARKINSON'S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL:
6.1 Hospital Pharmacies
6.2 Retailer Pharmacies
6.3 Online Pharmacies

7 GLOBAL PARKINSON'S DISEASE TREATMENT MARKET, BY DRUG CLASS:
7.1 Carbidopa/Levodopa
7.2 Dopamine Receptor Agonists
7.3 Mao Inhibitors
7.4 Comt Inhibitors
7.5 Anticholinergics
7.6 Other Drugs

8 GLOBAL PARKINSON'S DISEASE TREATMENTMARKET, BY GEOGRAPHY
8.1 Overview
8.2 North AmericaRegional Market Estimates and Forecasts, 2012 - 2025
8.2.1 U.S.
8.2.2 Canada
8.2.3 Mexico
8.3 EuropeRegional Market Estimates and Forecasts, 2012 - 2025
8.3.1 Germany
8.3.2 U.K.
8.3.3 France
8.3.4 Rest of Europe
8.4 Asia PacificRegional Market Estimates and Forecasts, 2012 - 2025
8.4.1 China
8.4.2 Japan
8.4.3 India
8.4.4 Rest of Asia Pacific
8.5 Latin AmericaRegional Market Estimates and Forecasts, 2012 - 2025
8.5.1 Brazil
8.5.2 Argentina
8.6 Rest of the WorldRegional Market Estimates and Forecasts, 2012 - 2025

9 GLOBAL PARKINSON'S DISEASE TREATMENTMARKETCOMPETITIVE LANDSCAPE
9.1 Overview
9.2 Company Market Share
9.3 Vendor Landscape
9.4 Key Development Strategies

10 COMPANY PROFILES
10.1 GSK
10.1.1 Overview
10.1.2 Financial Performance
10.1.3 Product Outlook
10.1.4 Key Developments

10.2 Merck
10.2.1 Overview
10.2.2 Financial Performance
10.2.3 Product Outlook
10.2.4 Key Developments

10.3 Novartis
10.3.1 Overview
10.3.2 Financial Performance
10.3.3 Product Outlook
10.3.4 Key Developments

10.4 Teva
10.4.1 Overview
10.4.2 Financial Performance
10.4.3 Product Outlook
10.4.4 Key Developments

10.5 BoehringerIngelheim
10.5.1 Overview
10.5.2 Financial Performance
10.5.3 Product Outlook
10.5.4 Key Developments

10.6 Impax
10.6.1 Overview
10.6.2 Financial Performance
10.6.3 Product Outlook
10.6.4 Key Developments

10.7 Abbvie
10.7.1 Overview
10.7.2 Financial Performance
10.7.3 Product Outlook
10.7.4 Key Developments

10.8 Valeant Pharmaceuticals
10.8.1 Overview
10.8.2 Financial Performance
10.8.3 Product Outlook
10.8.4 Key Developments

10.9 Lundbeck
10.9.1 Overview
10.9.2 Financial Performance
10.9.3 Product Outlook
10.9.4 Key Development

10.10 Sun Pharma
10.10.1 Overview
10.10.2 Financial Performance
10.10.3 Product Outlook
10.10.4 Key Development

10.11 Wockhardt
10.11.1 Overview
10.11.2 Financial Performance
10.11.3 Product Outlook
10.11.4 Key Development

10.12 Acadia
10.12.1 Overview
10.12.2 Financial Performance
10.12.3 Product Outlook
10.12.4 Key Development

10.13 UCB
10.13.1 Overview
10.13.2 Financial Performance
10.13.3 Product Outlook
10.13.4 Key Development

11 Appendix
11.1 Related Reports